The usage of Tamoxifen has been decreasing over time due to the emergence of selective ER degraders (SERDs) like fulvestrant and better aromatase inhibition drugs, and it is now primarily utilized as an adjuvant treatment for lower-risk premenstrual breast cancer and as a preventive treatment [24]. This evidence concerns the gene ESR1 and breast carcinoma.